Trevi

TRVI NASDAQ
4.640
+0.240
+5.45%
已收盘, 16:00 08/16 EDT
开盘
4.500
昨收
4.400
最高
4.650
最低
4.420
成交量
9,369
成交均量(3M)
4.31万
52周最高
10.62
52周最低
4.040
换手率
0.05%
市值
8,246.09万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Trevi TRVI股票价格,Trevi股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat neurologically mediated conditions. The Company is engaged in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID), in patients with Parkinson’s disease. The Company is conducting a Phase 2b/3 clinical trial of nalbuphine ER. The Company has also commenced a Phase 1b clinical trial in patients with chronic liver disease to evaluate the safety, pharmacokinetics and anti-pruritic effect of nalbuphine ER in this population. The Company’s nalbuphine ER development programs are Chronic Pruritus Programs, Prurigo Nodularis Program, Pruritus in Chronic Liver Disease Program and Uremic Pruritus Program.
展开 >

最近浏览

名称
价格
涨跌幅